Skip to main content
Caplight Logo









EveliQure Biotechnologies

EveliQure Biotechnologies

Private
ViennaHealthcare & Life Scienceshttps://www.eveliqure.com/

Last Round

Strategic

Mar 20, 2026

Total Funding Raised

$37.13M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

EveliQure Biotechnologies is a clinical-stage biotechnology company that develops innovative vaccine technology platforms to prevent diarrheal diseases caused by enteric pathogens such as Shigella and ETEC.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

vaccine developmentlive-attenuated vaccinebiotechinfectious diseaseshigellosisETECclinical-stage biotechvaccine candidateenterotoxigenic escherichia colidiarrheal diseasedrug discoverypharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EveliQure Biotechnologies Comparables

Compare EveliQure Biotechnologies with similar companies based on industry and business-model similarity.

EveliQure Biotechnologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Scandinavian Biopharma
87%
Eli Lilly and Company
82%
MecVax
79%

EveliQure Biotechnologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicMar 20, 2026
GrantSep 9, 2020
VC RoundJul 2, 2020
GrantNov 5, 2019
GrantSep 10, 2019
Grant
Jan 1, 2019

Key People

Founding team and executive leadership

Gabor Somogyi

Chief Executive Officer

Executive Team

EveliQure Biotechnologies Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 44% MoM.

  • Mar 20, 2026

    Serum Institute of India led the strategic round.

EveliQure Biotechnologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

EveliQure Biotechnologies Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersVienna
Employee Range6
Year FoundedN/A
Last FundingMar 20, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?